JP Selects Secures Exclusive Rights to Market Kardashian Health and Beauty Products in the UK, China, India and Pakistan
Tue 17th Jan 2012
ROK Global PLC, the mobile and web technologies, applications and services company, has announced its online eco-friendly products retail division, JP Selects, has secured the exclusive distribution rights from Windmill Health Products LLC to market Kardashian Glamour Tan, Monte Carlo Self-Tanner, Idol White and Dermapure Crème, Dermapure Serum health and beauty products in the United Kingdom, China, India and Pakistan.
Jonathan Kendrick, Chairman and CEO of ROK said “As we develop our eco-friendly and sustainable brands and products business via our fast-growing, members-only, JP Selects portal, the opportunity exists for us to develop and deploy a select number of our partner brands internationally and, to secure the exclusive rights to these already successful and proven health and beauty products, represents a major and significant opportunity for huge business growth.”
ROK Global, listed on the Open Market of the Frankfurt Stock Exchange, was co-founded by US Billionaire John Paul DeJoria, the co-founder of Paul Mitchell hair care systems and Patron Tequila and UK serial technology entrepreneur, Jonathan Kendrick.
“We are delighted to have secured the marketing and sales support of JP Selects for these products which will provide us with a significant boost to our business internationally in these four major new markets.” Said Richard Lauritano , Vice President of Special Markets at Windmill Health Products.
In addition to JP Selects, ROK has pioneered the development of several innovative mobile and web technologies including high quality Mobile TV which streams video over mass-market 2.5G GPRS as well as 3G and Wi-Fi, mobile-phone security and policing software which it licenses to law enforcement agencies and and highly innovative multi-language text-to-speech technologies.
Safe Harbor Statement;
The statements contained herein are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward- looking statements, including, but not limited to, certain delays beyond the company's control with respect to market acceptance of new technologies or products, delays in testing and evaluation of products, and other risks detailed from time to time.